CONNECT WITH US:
linkedin [#161] Created with Sketch.
Explore our easy-to-use
Supplier Directory
Oswego Health Promotes Sarah Driscoll to Director of Pharmacy
The Oswego Hospital Pharmacy serves patients within the hospital, Fulton and Central Square Urgent Cares, Seneca Hill Manor, Lobdell Center for Mental Health & Wellness at Lakeview, as well as Physician Care, PC
Oct 23, 2023
Sarah Driscoll

OSWEGO, NY - Oswego Health makes it a priority to recognize staff for their hard work and commitment to the organization and its patients. One key staff member who continues to shine and has truly stepped up is Sarah Driscoll.

Driscoll has been promoted to Director of Pharmacy at Oswego Health. Driscoll started at Oswego Health as a Staff Pharmacist in 2013, before transitioning in 2015 to the Pharmacy Operations Supervisor. In June of 2023 she was named Interim Director of Pharmacy.

Born and raised in Oswego, NY, Driscoll graduated with a Doctorate in Pharmacy in 2013 from Albany College of Pharmacy and Health Sciences. She has been a preceptor for the University of Buffalo School of Pharmacy, Albany College of Pharmacy, and St. John Fisher School of Pharmacy.

As the Director of Pharmacy, Driscoll will manage and direct the operations of the department to ensure that quality pharmaceutical services are provided to patients, in accordance with the mission and values of Oswego Health. Overseeing a department of seventeen, including six Pharmacists, Driscoll is looking forward to strengthening her team’s collaboration with providers and expanding the antibiotics stewardship program within the community.

The Oswego Hospital Pharmacy serves patients within the hospital, Fulton and Central Square Urgent Cares, Seneca Hill Manor, Lobdell Center for Mental Health & Wellness at Lakeview, as well as Physician Care, PC.

Latest Industry news
View all Industry News
Bayer Logo
AskBio Earns FDA Rare Pediatric & Orphan Drug Status for AB-1003 in Limb-Girdle Muscular Dystrophy
Nov 07, 2024

Research Triangle Park, N.C.  – Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that AB-1003 (also known as LION-101) has received rare pediatric disease designation and orphan-drug designation from the US Food and Drug Administration (FDA) for the treatment of limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).

hotomicrograph of bone marrow aspirate showing myeloblasts of acute myeloid leukemia (AML), a cancer of white blood cells.
FDA grants accelerated approval to asciminib for newly diagnosed chronic myeloid leukemia
Nov 01, 2024

The Food and Drug Administration granted accelerated approval to asciminib (Scemblix, Novartis AG) for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP).

White oxy pills
Protega Pharmaceuticals Gains FDA Approval for Abuse-Deterrent ROXYBOND™ 10 mg Pain Tablet
Oct 29, 2024

PRINCETON, N.J - Protega Pharmaceuticals Inc. recently announced that the U.S. Food and Drug Administration (FDA) has approved ROXYBOND™ (oxycodone hydrochloride) immediate-release (IR) CII 10 mg tablet for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. ROXYBOND is the first and only FDA-approved abuse-deterrent IR 10 mg oxycodone formulation that is expected to reduce abuse by intranasal and intravenous routes.